| Name | Title | Contact Details |
|---|---|---|
Kevin Duvall |
ARPA-H Chief Information Officer | Profile |
Kevin Duvall |
Acting Chief Technology Officer and Chief Information Officer | Profile |
Eastern Maine Medical Center Federal Credit Union aka EMMC FCU is a Bangor, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.
Two Pore Guys has created a digital, hand-held, single molecule biosensor that rivals the sensitivity of expensive medical lab equipment, yet is as inexpensive and easy to use as a blood glucose monitor.
Athens Research and Technology is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.